Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too.Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.

COM:CRINETICS